Portfolio company Abzena, which provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, and the Baylor Scott & White Research Institute have announced the formation of a joint venture company, Denceptor Therapeutics Limited.
Denceptor will develope novel immunotherapeutic products for the treatment of cancers and autoimmune disesases by combining Abezena's Composite Human Antibody Technology™ to reduce unwanted effects from the Baylor Scott & White Research Institute’s dendritic cell receptor-targeting antibodies.
Denceptor is expected to be based in Cambridge, UK and will seek third party funding to support the clinical development of its lead product, an HPV E6/E7 immunotherapy for head and neck cancer and other HPV-associated malignancies.
Dr John Burt, CEO of Abzena, said:
“We have a longstanding relationship with Baylor and have always admired the work they do and recognise their significant expertise in the field of dendritic cell research. We believe that through this joint venture Abzena can make a significant contribution to the development of new, smart, immunotherapies to tackle difficult to treat conditions such as cancer and autoimmune diseases.”